Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 182

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Experience with‘triple’ anti‐Helicobacter pylori eradication therapy: side effects and the importance of testing the pre‐treatment bacterial isolate for metronidazole resistance

BELL, G. D., POWELL, K., BURRIDGE, S. M., PALLECAROS, A., JONES, P. H., GANT, P. W., HARRISON, G., TROWELL, J. E.·1992·Alimentary Pharmacology & Therapeutics

Abstract

SUMMARY: At the 1990 World Congresses of Gastroenterology, the Working Party on Helicobacter pylori (H. pylori) recommended that, in suitable patients, the bacterium should be eradicated using a therapeutic regimen comprising a bismuth salt, tetracycline and metronidazole for two weeks. We have treated 40 patients infected with H. pylori with‘triple’ therapy consisting of 120 mg tripotassium dicitrato bismuthate q.d.s., 500 mg tetracycline q.d.s. and 400 mg metronidazole t.d.s. for two weeks. The success rate, in terms of bacterial eradication, was 19/21 (90.5%) in patients with metronidazole‐sensitive organisms, compared with only 6/19 (31.6%) in patients whose H. pylori were resistant to metronidazole (P < 0.01). Side effects, particularly diarrhoea and vomiting/nausea, were common: 23/40 patients reported such symptoms during the 14‐day course of therapy. Fifteen of these 23 patients completed the entire 14‐day course, although suffering from significant side effects, while the remaining eight patients had to discontinue the treatment because side effects became intolerable. If a form of triple therapy is going to be widely used to eradicate H. pylori infection, the regimen will have to be simpler, shorter, produce fewer side effects and be more effective in patients with metronidazole‐resistant bacteria.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.1992.tb00556.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 182

Metadata

Authors
BELL, G. D., POWELL, K., BURRIDGE, S. M., PALLECAROS, A., JONES, P. H., GANT, P. W., HARRISON, G., & TROWELL, J. E.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
1992-08
Volume
6
Issue
4
Pages
427-435
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2007892598
Cited by
182
References
2
FWCI
19.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Experience with‘triple’ anti‐Helicobacter pylori eradication therapy: side effects and the importance of testing the pre‐treatment bacterial isolate for metronidazole resistance. https://app.cochat.ai/papers/10.1111/j.1365-2036.1992.tb00556.x
The paper
BELL, G. D., POWELL, K., BURRIDGE, S. M., PALLECAROS, A., JONES, P. H., GANT, P. W., HARRISON, G., & TROWELL, J. E. (1992). Experience with‘triple’ anti‐Helicobacter pylori eradication therapy: side effects and the importance of testing the pre‐treatment bacterial isolate for metronidazole resistance. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.1992.tb00556.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.